As the interest of ag-bio firms in RNAi and microRNA technologies heats up, crop sciences firm Syngenta has made an all-cash bid to acquire Devgen and its portfolio of RNAi-based crop-enhancement and -protection technologies.

According to Syngenta, it aims to buy all Devgen shares and warrants at a price of €16 ($20.70) per share, which represents a 70 premium on Devgen's stock on NYSE Euronext Brussels prior to the disclosure of the offer. The total value of the deal is estimated at around €400 million ($518 million).

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PNAS this week: spatiotemporal study of lncRNA expression, role of extrachromosomal, circular DNAs in yeast, and more.

A European team has launched a four-year study to develop a test to gauge cervical, ovarian, uterine, or aggressive breast cancer risk in women.

As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.

In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.